- Clifford J. Stocks - Chief Executive Officer
Clifford J. Stocks
Chief Executive Officer
Mr. Stocks brings more than twenty-five years of experience in the biotech industry to OncoResponse. Most recently, Mr. Stocks served as Chief Executive Officer at Theraclone Sciences, where he was responsible for leading all aspects of the company’s efforts to discover and develop novel therapeutic antibody immunotherapies for the treatment of infectious disease. Prior to Theraclone, Mr. Stocks served as Chief Business Officer of Calistoga Pharmaceuticals, Inc., where he led the partnering activities and M&A teamwork that resulted in the acquisition of Calistoga by Gilead for $600 million in Q2 2011. Prior to Calistoga, Mr. Stocks spent over 15 years at ICOS Corporation, where he served as an Executive Officer and Vice President of Business Development. While at ICOS, he led acquisitions and joint venture activities, as well as alliance formation, strategy, licensing and deal making. He played an instrumental role on the leadership team that developed and launched Cialis®, and was a key architect of the Lilly ICOS joint venture partnership leading to the $2.3 billion acquisition of ICOS in 2007. Mr. Stocks's early career includes a turn as a management consultant in the Health Services practice of Booz, Allen & Hamilton, as well as academic research in the department of immunology at the University of Utah and the department of molecular genetics and cell biology at the University of Chicago.
Mr. Stocks received a Master of Business Administration degree from the University of Chicago, Booth Graduate School of Business and a Bachelor of Science degree in biology from the University of Utah.
- anil singHAl, Ph.D. - Chief Scientific Officer
Anil Singhal, Ph.D.
Chief Scientific Officer
Dr. Singhal is the former Vice President of Early Oncology Development at AbbVie and Head of AbbVie-Redwood City site. During his tenure at AbbVie, he oversaw the global regulatory approvals of Empliciti in multiple myeloma and Zinbryta in multiple sclerosis. As a member of the R&D leadership team, he helped to build an impressive portfolio and key translational science capabilities in oncology, immunology and other diseases. Dr. Singhal has held senior roles in the US, Japanese and German biopharma / biotechnology industry for over 30 years leading to the approval of Prosorba in rheumatoid arthritis and talaporfin sodium in non-small cell lung cancer. Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington.
Dr. Singhal is passionate about the translation of novel science into transforming medicines for cancer patients. He holds a Ph.D. from Wakesman Institute of Rutgers University and an Executive MBA from University of Washington.
- Russ Hawkinson - Chief Financial Officer
Chief Financial Officer
Mr. Hawkinson is an experienced financial executive with over 17 years of experience in the life sciences industry. Most recently, Mr. Hawkinson served as Chief Financial Officer of Theraclone Sciences, where he led all areas of finance, strategy, and corporate development. Prior to Theraclone, Mr. Hawkinson was Vice President, Finance and Accounting at CTI Biopharma, where he was responsible for SEC reporting, Treasury, and finance functions. Previously, Mr. Hawkinson was Vice President, Finance at Corixa Corporation, where he directed the finance and accounting functions, including all aspects of planning and reporting, operational accounting, and oversight of all SEC-related activities. Prior to Corixa, Mr. Hawkinson was an audit senior manager at Ernst & Young.
Mr. Hawkinson earned his B.A. from the University of Washington and received his CPA in Washington State.
- KAMAL D. PURI, PH.D. - VICE PRESIDENT, RESEARCH AND DEVELOPMENT
Kamal D. Pudi, PhD
Vice President, Research and Development
Dr. Puri joined Oncoresponse from Celgene where he led a preclinical research group to discover new molecular entities for the immunology pipeline as well as identified and supported new indications for existing portfolio molecules. Prior to Celgene he was Associate Director of Research at Gilead, where he contributed to the approval of Zydelig™ a first-in-class PI3K delta inhibitor for the treatment of hematological malignancies. Dr. Puri also led internal teams and managed external collaborations to deliver a best-in-class PI3K delta inhibitor and advanced it into clinical development, and directed research efforts on multiple discovery projects in inflammation. Prior to Gilead, which acquired Calistoga Pharma, Dr. Puri was Head of Biology at Calistoga and was responsible for a wide range of activities including preclinical research and portfolio strategy and biomarker discovery with success in advancing three drug candidates into clinical development for multiple indications. Earlier in his career, Dr. Puri also led drug discovery efforts at ICOS Corporation and CytoTherapeutics.
Dr. Puri received his Ph.D. from Indian Institute of Science, Bangalore, India. During his research period, he was a Research Fellow of the Council of Scientific and Industrial Research, India. Dr. Puri undertook his immunology training with Timothy A. Springer, Ph.D. Latham Family Professor at the Harvard Medical School.